Sigma Healthcare Ltd (SIG) - Net Assets
Based on the latest financial reports, Sigma Healthcare Ltd (SIG) has net assets worth AU$4.89 Billion AUD (≈ $3.46 Billion USD) as of October 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$8.74 Billion ≈ $6.18 Billion USD) and total liabilities (AU$3.85 Billion ≈ $2.72 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check tangible net worth ratio of Sigma Healthcare Ltd to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | AU$4.89 Billion |
| % of Total Assets | 55.97% |
| Annual Growth Rate | 4.89% |
| 5-Year Change | 63.17% |
| 10-Year Change | 51.59% |
| Growth Volatility | 710.01 |
Sigma Healthcare Ltd - Net Assets Trend (2000–2025)
This chart illustrates how Sigma Healthcare Ltd's net assets have evolved over time, based on quarterly financial data. See Sigma Healthcare Ltd defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Sigma Healthcare Ltd (2000–2025)
The table below shows the annual net assets of Sigma Healthcare Ltd from 2000 to 2025. For live valuation and market cap data, see market value of Sigma Healthcare Ltd.
| Year | Net Assets | Change |
|---|---|---|
| 2025-01-31 | AU$839.28 Million ≈ $593.84 Million |
-3.82% |
| 2024-01-31 | AU$872.61 Million ≈ $617.43 Million |
+82.64% |
| 2023-01-31 | AU$477.77 Million ≈ $338.05 Million |
-2.25% |
| 2022-01-31 | AU$488.78 Million ≈ $345.84 Million |
-4.97% |
| 2021-01-31 | AU$514.36 Million ≈ $363.94 Million |
+7.89% |
| 2020-01-31 | AU$476.74 Million ≈ $337.32 Million |
-7.30% |
| 2019-01-31 | AU$514.28 Million ≈ $363.89 Million |
-0.19% |
| 2018-01-31 | AU$515.26 Million ≈ $364.58 Million |
-4.33% |
| 2017-01-31 | AU$538.59 Million ≈ $381.08 Million |
-2.72% |
| 2016-01-31 | AU$553.65 Million ≈ $391.75 Million |
-3.38% |
| 2015-01-31 | AU$573.00 Million ≈ $405.43 Million |
-1.01% |
| 2014-01-31 | AU$578.83 Million ≈ $409.56 Million |
-5.24% |
| 2013-01-31 | AU$610.81 Million ≈ $432.18 Million |
-10.51% |
| 2012-01-31 | AU$682.53 Million ≈ $482.93 Million |
-18.06% |
| 2011-01-31 | AU$832.92 Million ≈ $589.34 Million |
-21.93% |
| 2010-01-31 | AU$1.07 Billion ≈ $754.94 Million |
-10.93% |
| 2009-01-31 | AU$1.20 Billion ≈ $847.61 Million |
-0.23% |
| 2008-01-31 | AU$1.20 Billion ≈ $849.54 Million |
-10.70% |
| 2007-01-31 | AU$1.34 Billion ≈ $951.29 Million |
+5.93% |
| 2006-01-31 | AU$1.27 Billion ≈ $898.02 Million |
+3621.02% |
| 2005-01-31 | AU$34.11 Million ≈ $24.13 Million |
+25.10% |
| 2004-01-31 | AU$27.27 Million ≈ $19.29 Million |
+85.14% |
| 2003-01-31 | AU$14.73 Million ≈ $10.42 Million |
+36.15% |
| 2002-01-31 | AU$10.82 Million ≈ $7.65 Million |
-95.68% |
| 2001-01-31 | AU$250.64 Million ≈ $177.35 Million |
-1.52% |
| 2000-01-31 | AU$254.51 Million ≈ $180.08 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Sigma Healthcare Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3453.3% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (January 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | AU$1.68 Billion | 200.79% |
| Other Comprehensive Income | AU$-3.68 Million | -0.44% |
| Total Equity | AU$837.86 Million | 100.00% |
Sigma Healthcare Ltd Competitors by Market Cap
The table below lists competitors of Sigma Healthcare Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
First Solar Inc
NASDAQ:FSLR
|
$23.63 Billion |
|
Novonesis (Novozymes) A/S
CO:NSIS-B
|
$23.64 Billion |
|
Reddit, Inc.
NYSE:RDDT
|
$23.67 Billion |
|
Fresenius SE & Co. KGaA
XETRA:FRE
|
$23.68 Billion |
|
YPF S.A. D
BA:YPFD
|
$23.58 Billion |
|
Hexagon AB (publ)
ST:HEXA-B
|
$23.54 Billion |
|
Qinghai Salt Lake Industry Co.Ltd
SHE:000792
|
$23.42 Billion |
|
QBE Insurance Group Ltd
AU:QBE
|
$23.39 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Sigma Healthcare Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 870,770,000 to 837,860,000, a change of -32,910,000 (-3.8%).
- Net loss of 13,842,000 reduced equity.
- Dividend payments of 17,132,000 reduced retained earnings.
- Share repurchases of 2,682,000 reduced equity.
- New share issuances of 2,682,000 increased equity.
- Other comprehensive income decreased equity by 6,603,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | AU$-13.84 Million | -1.65% |
| Dividends Paid | AU$17.13 Million | -2.04% |
| Share Repurchases | AU$2.68 Million | -0.32% |
| Share Issuances | AU$2.68 Million | +0.32% |
| Other Comprehensive Income | AU$-6.60 Million | -0.79% |
| Other Changes | AU$4.67 Million | +0.56% |
| Total Change | AU$- | -3.78% |
Book Value vs Market Value Analysis
This analysis compares Sigma Healthcare Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 54.21x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 4196.18x to 54.21x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2002-01-31 | AU$0.00 | AU$2.89 | x |
| 2003-01-31 | AU$0.00 | AU$2.89 | x |
| 2004-01-31 | AU$0.00 | AU$2.89 | x |
| 2005-01-31 | AU$0.00 | AU$2.89 | x |
| 2006-01-31 | AU$0.08 | AU$2.89 | x |
| 2007-01-31 | AU$0.13 | AU$2.89 | x |
| 2008-01-31 | AU$0.12 | AU$2.89 | x |
| 2009-01-31 | AU$0.08 | AU$2.89 | x |
| 2010-01-31 | AU$0.11 | AU$2.89 | x |
| 2011-01-31 | AU$0.07 | AU$2.89 | x |
| 2012-01-31 | AU$0.06 | AU$2.89 | x |
| 2013-01-31 | AU$0.04 | AU$2.89 | x |
| 2014-01-31 | AU$0.05 | AU$2.89 | x |
| 2015-01-31 | AU$0.05 | AU$2.89 | x |
| 2016-01-31 | AU$0.05 | AU$2.89 | x |
| 2017-01-31 | AU$0.05 | AU$2.89 | x |
| 2018-01-31 | AU$0.05 | AU$2.89 | x |
| 2019-01-31 | AU$0.05 | AU$2.89 | x |
| 2020-01-31 | AU$0.05 | AU$2.89 | x |
| 2021-01-31 | AU$0.05 | AU$2.89 | x |
| 2022-01-31 | AU$0.05 | AU$2.89 | x |
| 2023-01-31 | AU$0.05 | AU$2.89 | x |
| 2024-01-31 | AU$0.08 | AU$2.89 | x |
| 2025-01-31 | AU$0.05 | AU$2.89 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Sigma Healthcare Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -1.65%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -0.28%
- • Asset Turnover: 2.67x
- • Equity Multiplier: 2.18x
- Recent ROE (-1.65%) is below the historical average (14.31%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2000 | 4.10% | 0.68% | 2.81x | 2.14x | AU$-15.01 Million |
| 2001 | 3.57% | 0.50% | 2.95x | 2.43x | AU$-16.12 Million |
| 2002 | 49.02% | 3.85% | 2.44x | 5.22x | AU$4.22 Million |
| 2003 | 61.36% | 3.65% | 3.86x | 4.36x | AU$7.56 Million |
| 2004 | 45.98% | 4.76% | 3.25x | 2.97x | AU$9.81 Million |
| 2005 | 174.66% | 17.71% | 3.40x | 2.90x | AU$56.16 Million |
| 2006 | 8.26% | 4.78% | 1.12x | 1.54x | AU$-22.07 Million |
| 2007 | 7.57% | 3.72% | 1.32x | 1.54x | AU$-32.66 Million |
| 2008 | 6.43% | 2.58% | 1.45x | 1.72x | AU$-42.91 Million |
| 2009 | 6.69% | 2.58% | 1.41x | 1.84x | AU$-39.67 Million |
| 2010 | -36.46% | -11.93% | 1.69x | 1.81x | AU$-495.74 Million |
| 2011 | -28.26% | -8.01% | 1.89x | 1.86x | AU$-318.67 Million |
| 2012 | 7.20% | 1.71% | 2.66x | 1.58x | AU$-19.08 Million |
| 2013 | 3.06% | 0.63% | 2.81x | 1.73x | AU$-42.39 Million |
| 2014 | 9.25% | 1.80% | 3.15x | 1.63x | AU$-4.35 Million |
| 2015 | 9.21% | 1.68% | 2.98x | 1.84x | AU$-4.53 Million |
| 2016 | 9.15% | 1.46% | 3.12x | 2.01x | AU$-4.71 Million |
| 2017 | 9.91% | 1.22% | 3.90x | 2.08x | AU$-492.30K |
| 2018 | 10.73% | 1.34% | 3.14x | 2.54x | AU$3.75 Million |
| 2019 | 7.12% | 0.92% | 2.87x | 2.70x | AU$-14.81 Million |
| 2020 | -2.59% | -0.38% | 2.64x | 2.58x | AU$-59.93 Million |
| 2021 | 8.47% | 1.28% | 2.79x | 2.37x | AU$-7.84 Million |
| 2022 | -1.49% | -0.21% | 2.70x | 2.62x | AU$-55.96 Million |
| 2023 | 0.38% | 0.05% | 3.05x | 2.52x | AU$-45.78 Million |
| 2024 | 0.52% | 0.14% | 2.37x | 1.61x | AU$-82.57 Million |
| 2025 | -1.65% | -0.28% | 2.67x | 2.18x | AU$-97.63 Million |
Industry Comparison
This section compares Sigma Healthcare Ltd's net assets metrics with peer companies in the Medical Distribution industry.
Industry Context
- Industry: Medical Distribution
- Average net assets among peers: $288,224,691
- Average return on equity (ROE) among peers: -33.03%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Sigma Healthcare Ltd (SIG) | AU$4.89 Billion | 4.10% | 0.79x | $23.61 Billion |
| Cyclopharm Ltd (CYC) | $42.73 Million | -30.89% | 0.45x | $58.87 Million |
| Ebos Group Ltd (EBO) | $94.15 Million | 10.96% | 0.46x | $2.30 Billion |
| Mayne Pharma Group Ltd (MYX) | $1.01 Billion | -27.53% | 0.61x | $129.34 Million |
| Paragon Care Ltd (PGC) | $1.94 Million | -84.65% | 0.24x | $175.69 Million |
About Sigma Healthcare Ltd
Sigma Healthcare Limited operates as a retail pharmacy franchisor and pharmaceutical wholesale and distributor to community pharmacies primarily in Australia. It offers support services to a network of franchised retail pharmacies; third and fourth party logistics services to pharmaceutical manufacturers and other supplier partners; and health services. The company operates stores under the Chemi… Read more